Difference between revisions of "Lomustine (CCNU)"

Revision as of 02:55, 9 December 2014

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

Also known as

Also known as CCNU.

In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.^[5] Lomustine will be supplied as CCNU by NextSource Biotechnology.^[6]

References

[insert-1] 1.0 ^1.1 Lomustine (Ceenu) package insert

[2] Lomustine (Ceenu) package insert (locally hosted backup)

[3] Lomustine (Ceenu) patient drug information (Chemocare)

[4] Lomustine (Ceenu) patient drug information (UpToDate)

[5] Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)

[6] NextSource Biotechnology Lomustine (CCNU) update

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 23: / Line 23: @@
 [[Category:Drug index]]
 [[Category:Chemotherapy]]
+[[Category:Oral chemotherapy]]
 [[Category:Nitrosureas]]
 [[Category:Central nervous system (CNS) cancer medications]]
 [[Category:Central nervous system (CNS) lymphoma medications]]
+[[Category:Drugs FDA approved in 1976]]